Biomanufacturing – harnessing biological processes in cells and microbes to design and manufacture products – is revolutionizing how we make everything from futuristic consumer goods to sustainable fuels to breakthrough medicines. Every biomanufactured product can be traced back to discoveries in the lab, but translating that science into a real-world product can be tricky. Berkeley Lab is helping to move great ideas, like outdoor gear made from algae oil, from conception to commercialization.
A new test agent can easily and efficiently detect the misfolded protein aggregates that cause devastating neurological diseases in blood samples. The technology could lead to early diagnosis of prion, Alzheimer’s, and Parkinson’s diseases for the first time.
The unique ways in which proteins fold dictate their interplay with diseases and medicines, so understanding their twists and turns is key to designing effective drugs. While new drug design is serious work, discovering how proteins fold can be fun, too: A crowdsourcing game called Foldit allows players to try different fold configurations for points
This video and accompanying article highlight the decades of discoveries, achievements and progress in particle accelerator R&D at Berkeley Lab. These accelerators have enabled new explorations of the atomic nucleus; the production and discovery of new elements and isotopes, and of subatomic particles and their properties; created new types of medical imaging and treatments; and provided new insight into the nature of matter and energy, and new methods to advance industry and security, among other wide-ranging applications.
Nearly ten years ago, a group of Israeli clinical researchers emailed Berkeley Lab geneticist Len Pennacchio to ask for his team’s help in solving the mystery of a rare inherited disease that caused extreme, and sometimes fatal, chronic diarrhea in children. Now, following an arduous investigative odyssey that expanded our understanding of regulatory sequences in the human genome, the multinational scientific group has announced the discovery of the genetic explanation for this disease.
Scientists have invented a new “synthetic antibody” that could make screening for diseases easier and less expensive than current go-to methods. Writing in the journal Nano Letters, a team led by Markita Landry of Berkeley Lab and UC Berkeley describes how peptoids – synthetically produced molecules, first created by Ron Zuckermann at Berkeley Lab’s Molecular Foundry, that
Mice have been instrumental in the study of cancer, but like all animal models of human diseases, they have their limitations. For stomach cancer in particular, mice have historically been regarded as quite poor research organisms because rodents rarely develop spontaneous stomach tumors. But results from a new study are about to shake up the paradigm.